Influenza and influenza vaccination in children
Ecological and active population-based surveillance studies have clearly shown the large burden of influenza disease in children, both in hospital and outpatient settings. Mortality and encephalitis due to influenza have also been reported. Two vaccines are licensed for use in children; trivalent inactivated and live attenuated vaccines. Both have been shown to be efficacious for the prevention of clinically and laboratory-confirmed influenza. In recent comparative trials in young children, live attenuated vaccines were shown to be more effective than trivalent inactivated vaccines for the prevention of laboratory-confirmed influenza. However, episodes of wheezing were increased in the youngest children receiving live attenuated vaccine. Trivalent inactivated influenza vaccine has an excellent safety profile and has been mainly associated with local pain and tenderness at the injection site. Vaccine efficacy for the inactivated vaccine has been shown to be greater in older children. Increased use of either influenza vaccine has the potential to reduce the disease burden in children and to extend herd protection to those who are not vaccinated.
KeywordsInfluenza Vaccination Live Attenuate Influenza Vaccine Inactivate Influenza Vaccine Trivalent Inactivate Influenza Vaccine Live Attenuate Vaccine
Unable to display preview. Download preview PDF.
- 3.Iwane MK, Edwards KM, Szilagyi PG, Walker FJ, Griffin MR, Weinberg GA, Coulen C, Poehling KA, Shone LP, Balter S et al (2004) New Vaccine Surveillance Network. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics 113: 1758–1764PubMedCrossRefGoogle Scholar
- 6.Weinberg GA, Erdman DD, Edwards KM, Hall CB, Walker FJ, Griffin MR, Schwartz B, New Vaccine Surveillance Network Study Group (2004) Superiority of reverse-transcription polymerase chain reaction to conventional viral culture in the diagnosis of acute respiratory tract infections in children. J Infect Dis 189: 706–710PubMedCrossRefGoogle Scholar
- 8.Bonner AB, Monroe KW, Talley LI, Klasner AE, Kimberlin DW (2003) Impact of the rapid diagnosis of influenza on physician decision-making and patient management in the pediatric emergency department: Results of a randomized, prospective, controlled trial. Pediatrics 112: 363–367PubMedCrossRefGoogle Scholar
- 10.Schrag SJ, Shay DK, Gershman K, Thomas A, Craig AS, Schaffner W, Harrison LH, Vugia D, Clogher P, Lynfield R et al (2006) Emerging Infections Program Respiratory Diseases Activity. Multistate surveillance for laboratory-confirmed, influenza-associated hospitalizations in children: 2003-2004. Pediatr Infect Dis J 25: 395–400PubMedCrossRefGoogle Scholar
- 31.Hoberman A, Greenberg DP, Paradise JL, Rockette HE, Lave JR, Kearney DH, Colborn DK, Kurs-Lasky M, Haralam MA, Byers CJ et al (2003) Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: A randomized controlled trial. JAMA 290: 1608–1616PubMedCrossRefGoogle Scholar
- 38.Ashkenazi S, Vertruyen A, Arístegui J, Esposito S, McKeith DD, Klemola T, Biolek J, Kühr J, Bujnowski T, Desgrandchamps D et al (2006) Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 25: 870–879PubMedCrossRefGoogle Scholar
- 39.Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, Øymar K, Garcia ML, Krygier A, Costa H et al (2006) Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 25: 860–869PubMedCrossRefGoogle Scholar
- 40.Tam JS, Capeding MR, Lum LC, Chotpitayasunondh T, Jiang Z, Huang LM, Lee BW, Qian Y, Samakoses R, Lolekha S et al (2007) Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J 26: 619–628PubMedCrossRefGoogle Scholar
- 42.Piedra PA, Gaglani MJ, Riggs M, Herschler G, Fewlass C, Watts M, Kozinetz C, Hessel C, Glezen WP (2005) Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics 116: e397–407CrossRefGoogle Scholar
- 46.Jackson LA, Neuzil KM, Baggs J, Davis RL, Black S, Yamasaki KM, Belongia E, Zangwill KM, Mullooly J, Nordin J et al (2006). Compliance with the recommendations for 2 doses of trivalent inactivated influenza vaccine in children less than 9 years of age receiving influenza vaccine for the first time: A Vaccine Safety Datalink study. Pediatrics 118: 2032–2037PubMedCrossRefGoogle Scholar